Stockscreener 앱 받기
4.22
0.47%
-0.02
시간 외 거래:
4.23
0.01
+0.24%
Cytomx Therapeutics Inc 주식(CTMX)의 최신 뉴스
Jefferies Maintains Buy on CytomX Therapeutics, Inc. (CTMX) $16 PT Mar 2026 - Meyka
Jefferies reiterates Buy rating on CytomX stock after phase 1 data - Investing.com Canada
CytomX Therapeutics (NASDAQ:CTMX) Given New $12.00 Price Target at Piper Sandler - MarketBeat
CTMX: Piper Sandler Raises Price Target to $12 | CTMX Stock News - GuruFocus
Piper Sandler raises CytomX stock price target on drug trial data - Investing.com Canada
CytomX Therapeutics launches $250M public offering - MSN
Stock Market Today, March 16: CytomX Therapeutics Surges After Positive Phase 1 Colorectal Cancer Data - AOL.com
How Investors Are Reacting To CytomX Therapeutics (CTMX) Equity Raise And Encouraging Varseta-M Trial Data - Sahm
A Look At CytomX Therapeutics (CTMX) Valuation After Positive Varsetatug Masetecan Phase 1 Expansion Results - Yahoo Finance
Jefferies Raises CytomX Therapeutics (CTMX) Price Target to $16 - Insider Monkey
CytomX Therapeutics prices $250M public offering at $5.30 per share - MSN
CTMX Stock Pulls Back After 5-Year High: Share Sale Sparks Dilution Fears Despite Wall Street’s 150% Upside Calls - Stocktwits
Cytomx Therapeutics Insider Sold Shares Worth $764,138, According to a Recent SEC Filing - marketscreener.com
CTMX Stock Chart | CYTOMX THERAPEUTICS INC (NASDAQ:CTMX) - ChartMill
Yu-Waye Chu Sells 21,279 Shares of CytomX Therapeutics (NASDAQ:CTMX) Stock - MarketBeat
Sean Mccarthy Sells 118,969 Shares of CytomX Therapeutics (NASDAQ:CTMX) Stock - MarketBeat
Sean McCarthy, CytomX Therapeutics CEO, sells $764k in stock By Investing.com - Investing.com Canada
CytomX therapeutics (CTMX) chief medical officer sells $136k in stock - Investing.com Canada
CytomX Therapeutics (NASDAQ:CTMX) CFO Sells $124,053.66 in Stock - MarketBeat
Insider Selling: CytomX Therapeutics (NASDAQ:CTMX) SVP Sells 31,492 Shares of Stock - MarketBeat
CytomX (CTMX) CMO sells 21,279 shares to cover RSU tax obligations - Stock Titan
CytomX Therapeutics SVP Belvin sells $202k in stock By Investing.com - Investing.com Australia
Ogden, CytomX Therapeutics CFO, sells $124k in shares - Investing.com
CytomX Therapeutics SVP Belvin sells $202k in stock - Investing.com
CytomX Therapeutics (CTMX) CEO sells shares to cover RSU tax obligations - Stock Titan
Tax-driven share sale by CytomX (CTMX) chief scientist on RSU vesting - Stock Titan
CytomX Therapeutics (CTMX) reports Q4 loss, misses revenue estimates - MSN
CytomX (NASDAQ: CTMX) CFO sells 19,323 shares for tax withholding - Stock Titan
CytomX Therapeutics Raises $234 Million in Equity Offering - TipRanks
Why Is CytomX Therapeutics Stock Falling On Wednesday? - Sahm
CytomX prices $5.30 public offering to raise ~$234.4M; includes pre-funded warrants - TradingView
CytomX (NASDAQ: CTMX) prices $234.4M stock and pre-funded warrant deal - Stock Titan
CytomX Therapeutics (NASDAQ:CTMX) Given New $16.00 Price Target at Barclays - MarketBeat
CytomX Therapeutics (NASDAQ:CTMX) Shares Gap Up After Analyst Upgrade - MarketBeat
CTMX Sees Price Target Raised to $16 by Jefferies Today | CTMX S - GuruFocus
Jefferies Maintains Buy on CTMX (CytomX Therapeutics) March 18, 2026 - Meyka
Latham Watkins Advises CytomX Therapeutics on Offering of Common Stock Pre Funded Warrants - Latham & Watkins LLP
CytomX (NASDAQ: CTMX) offers 45.99M shares and 1.18M pre‑funded warrants - Stock Titan
CTMX Stock Garners Price Target Revisions After Colorectal Cancer Trial Data: Jefferies Sees As Much As 230% Upside - Stocktwits
Analysts bullish ahead of colorectal cancer readout for CytomX Therapeutics, Inc. (CTMX) - MSN
CytomX Stocks Slide Amidst Profit Woes and Revenue Shortfall - timothysykes.com
CytomX Therapeutics (CTMX) Gets Price Target Boost from Guggenhe - GuruFocus
CTMX: Key Managers in Recent Offering - GuruFocus
Barclays raises its price target on CytomX Therapeutics, Inc. (CTMX) to $10 and maintains an overweight rating - MSN
CytomX Therapeutics (NASDAQ:CTMX) Sees Strong Trading Volume Following Analyst Upgrade - MarketBeat
CytomX Therapeutics: Great News, But Early Data Do Not Quite Justify This Price Level - Seeking Alpha
CytomX Therapeutics (NASDAQ:CTMX) Price Target Raised to $15.00 at Guggenheim - MarketBeat
HC Wainwright Has Bearish Estimate for CTMX Q1 Earnings - MarketBeat
CytomX Therapeutics Prices $250 Million Securities Offering; Shares Up Pre-Bell - marketscreener.com
CytomX prices $250M stock offering at $5.30 per share By Investing.com - Investing.com South Africa
CytomX Therapeutics Inc receives Investment Bank Analyst Rating Update By Investing.com - Investing.com
CytomX Therapeutics Confronts Rising AI Regulatory Risks and Cost Pressures - The Globe and Mail
Biotech CytomX prices $250M stock sale to fund Varseta-M - Stock Titan
CytomX Therapeutics (CTMX) Launches $250 Million Public Offering - GuruFocus
CTMX Analyst Rating Update: Wedbush Raises Price Target by 83% | - GuruFocus
CytomX prices $250M stock offering at $5.30 per share - Investing.com
CytomX Therapeutics prices public offering of 45,990,567 shares at $5.30 per share - marketscreener.com
CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants - Bitget
CytomX Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock - Quiver Quantitative
1.82%
자본화:
|
볼륨(24시간):